FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1503609683> ?p ?o ?g. }

• W1503609683 endingPage "1013" @default.
• W1503609683 startingPage "1008" @default.
• W1503609683 abstract "Experience with the use of platelet glycoprotein (GP) IIb-IIIa inhibitor eptifibatide in patients with ischemic stroke is limited. The authors report the off-label use of intraarterial eptifibatide during endovascular ischemic stroke revascularization procedures for reocclusion after documented recanalization or formed fresh thrombi in distal vessels that were inaccessible to endovascular devices.Patients who received intraarterial eptifibatide were identified from a prospectively collected database of patients in whom endovascular revascularization for acute ischemic stroke was attempted between 2005 and 2008. Data were analyzed retrospectively. The intraarterial eptifibatide dose was a single-bolus dose of 180 μg/kg body weight. Primary outcome measures were angiographic recanalization (Thrombolysis in Myocardial Infarction Grade 2 or 3), symptomatic intracranial hemorrhage rate, overall mortality rate, and favorable 3-month modified Rankin Scale score (≤ 2).The study included 35 patients (mean age 62 years, range 18-85 years). The median presenting National Institutes of Health Stroke Scale score was 13. Two patients received intravenous tissue plasminogen activator before endovascular therapy. The median time from symptom onset to therapy initiation was 230 minutes (range 90-1370 minutes). Twelve patients (34%) received intraarterial tissue plasminogen activator without mechanical measures. Mechanical revascularization measures used were Merci retriever in 19 (54%), Penumbra device in 1 (3%), balloon angioplasty in 15 (43%), and stent placement in 22 (63%) patients. The mean dose of intraarterial eptifibatide was 11.6 mg (range 5-16.6 mg). Partial-to-complete recanalization (Thrombolysis in Myocardial Infarction Grade 2 or 3) was achieved in 27 patients (77%). Postprocedure intracranial hemorrhage occurred in 13 patients (37%), causing symptoms in 5 (14%). In the 5 symptomatic intracranial hemorrhage cases, all patients but one presented more than 8 hours after symptom onset and all received intraarterial recombinant tissue plasminogen activator. The median discharge National Institutes of Health Stroke Scale score was 7 (range 0-17). At 3 months postprocedure, 21 patients (60%) had a modified Rankin Scale score ≤ 2, and 8 patients (23%) had died.Adjunctive intraarterial eptifibatide is a feasible option for salvage of reocclusion and thrombolysis of distal inaccessible thrombi during endovascular stroke revascularization. Its safety and efficacy need to be studied further in larger, multicenter, controlled studies." @default.
• W1503609683 created "2016-06-24" @default.
• W1503609683 creator A5017312638 @default.
• W1503609683 creator A5028101627 @default.
• W1503609683 creator A5037816826 @default.
• W1503609683 creator A5045616278 @default.
• W1503609683 creator A5045787148 @default.
• W1503609683 creator A5048566091 @default.
• W1503609683 creator A5069842789 @default.
• W1503609683 creator A5070286309 @default.
• W1503609683 date "2011-04-01" @default.
• W1503609683 modified "2023-09-25" @default.
• W1503609683 title "Safety and feasibility of intraarterial eptifibatide as a revascularization tool in acute ischemic stroke" @default.
• W1503609683 cites W1242868768 @default.
• W1503609683 cites W132472807 @default.
• W1503609683 cites W1642431645 @default.
• W1503609683 cites W1966189945 @default.
• W1503609683 cites W1966344675 @default.
• W1503609683 cites W1969698835 @default.
• W1503609683 cites W1972109636 @default.
• W1503609683 cites W1995462255 @default.
• W1503609683 cites W1998796974 @default.
• W1503609683 cites W2000094543 @default.
• W1503609683 cites W2015197224 @default.
• W1503609683 cites W2032308540 @default.
• W1503609683 cites W2036653122 @default.
• W1503609683 cites W2041674250 @default.
• W1503609683 cites W2042267799 @default.
• W1503609683 cites W2046166586 @default.
• W1503609683 cites W2085771291 @default.
• W1503609683 cites W2086437084 @default.
• W1503609683 cites W2094687142 @default.
• W1503609683 cites W2104736983 @default.
• W1503609683 cites W2107321252 @default.
• W1503609683 cites W2118910256 @default.
• W1503609683 cites W2119169574 @default.
• W1503609683 cites W2125478367 @default.
• W1503609683 cites W2138411396 @default.
• W1503609683 cites W2141186330 @default.
• W1503609683 cites W2142848477 @default.
• W1503609683 cites W2143086352 @default.
• W1503609683 cites W2143642806 @default.
• W1503609683 cites W2152389498 @default.
• W1503609683 cites W2317947810 @default.
• W1503609683 cites W2342256744 @default.
• W1503609683 cites W2398648430 @default.
• W1503609683 cites W2410059873 @default.
• W1503609683 cites W4235858444 @default.
• W1503609683 cites W4252057047 @default.
• W1503609683 cites W4254730674 @default.
• W1503609683 cites W4256202725 @default.
• W1503609683 doi "https://doi.org/10.3171/2010.8.jns10318" @default.
• W1503609683 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20868216" @default.
• W1503609683 hasPublicationYear "2011" @default.
• W1503609683 type Work @default.
• W1503609683 sameAs 1503609683 @default.
• W1503609683 citedByCount "23" @default.
• W1503609683 countsByYear W15036096832012 @default.
• W1503609683 countsByYear W15036096832013 @default.
• W1503609683 countsByYear W15036096832014 @default.
• W1503609683 countsByYear W15036096832015 @default.
• W1503609683 countsByYear W15036096832016 @default.
• W1503609683 countsByYear W15036096832017 @default.
• W1503609683 countsByYear W15036096832018 @default.
• W1503609683 countsByYear W15036096832019 @default.
• W1503609683 countsByYear W15036096832020 @default.
• W1503609683 countsByYear W15036096832021 @default.
• W1503609683 countsByYear W15036096832022 @default.
• W1503609683 crossrefType "journal-article" @default.
• W1503609683 hasAuthorship W1503609683A5017312638 @default.
• W1503609683 hasAuthorship W1503609683A5028101627 @default.
• W1503609683 hasAuthorship W1503609683A5037816826 @default.
• W1503609683 hasAuthorship W1503609683A5045616278 @default.
• W1503609683 hasAuthorship W1503609683A5045787148 @default.
• W1503609683 hasAuthorship W1503609683A5048566091 @default.
• W1503609683 hasAuthorship W1503609683A5069842789 @default.
• W1503609683 hasAuthorship W1503609683A5070286309 @default.
• W1503609683 hasBestOaLocation W15036096831 @default.
• W1503609683 hasConcept C126322002 @default.
• W1503609683 hasConcept C127413603 @default.
• W1503609683 hasConcept C141071460 @default.
• W1503609683 hasConcept C2776572282 @default.
• W1503609683 hasConcept C2779464278 @default.
• W1503609683 hasConcept C2779581417 @default.
• W1503609683 hasConcept C2780326628 @default.
• W1503609683 hasConcept C2780400711 @default.
• W1503609683 hasConcept C2780645631 @default.
• W1503609683 hasConcept C2780931571 @default.
• W1503609683 hasConcept C2781056559 @default.
• W1503609683 hasConcept C3020199598 @default.
• W1503609683 hasConcept C42219234 @default.
• W1503609683 hasConcept C500558357 @default.
• W1503609683 hasConcept C541997718 @default.
• W1503609683 hasConcept C71924100 @default.
• W1503609683 hasConcept C78519656 @default.
• W1503609683 hasConceptScore W1503609683C126322002 @default.
• W1503609683 hasConceptScore W1503609683C127413603 @default.
• W1503609683 hasConceptScore W1503609683C141071460 @default.

• next